A randomized, controlled, open-label, phase 2 study of cemiplimab +/- RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS). Haydon, A., Khushalani, N. I., Robert, C., Brungs, D., Collichio, F. A., Colevas, A., Lim, A., Kudchadkar, R., Chai-Ho, W., Daniels, G. A., Lutzky, J., Lee, J. J., Silk, A. W., Lebbe, C., Grob, J., Smith, M., Fury, M. G., Alamgeer, M., Hill, A., Migden, M. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680305149